These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33306634)

  • 1. Assessment of early oxidative stress following the use of radiotheranostics agents 177Lu-PSMA for prostate cancer and 177Lu-DOTATATE for neuroendocrine tumors; radioprotective effect of vitamin C.
    Jafari E; Ahmadzadehfar H; Bagheri D; Amini A; Assadi M
    Nucl Med Commun; 2021 Mar; 42(3):325-331. PubMed ID: 33306634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiotoxicity and cardiac monitoring following the use of radiotheranostics agents including 177Lu-PSMA for prostate cancer and 177Lu-DOTATATE for neuroendocrine tumors.
    Jafari E; Amini AL; Ahmadzadehfar H; Bagheri D; Assadi M
    Nuklearmedizin; 2021 Apr; 60(2):99-105. PubMed ID: 33461224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
    Kunikowska J; Królicki L; Hubalewska-Dydejczyk A; Mikołajczak R; Sowa-Staszczak A; Pawlak D
    Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1788-97. PubMed ID: 21553086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excellent Response to 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in a Patient With Progressive Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation After 177Lu-PSMA Therapy.
    Liu C; Liu T; Zhang J; Baum RP; Yang Z
    Clin Nucl Med; 2019 Nov; 44(11):876-878. PubMed ID: 31584494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
    Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
    Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood clearance and occupational exposure for
    Abuqbeitah M; Demir M; Uslu-Beşli L; Yeyin N; Sönmezoğlu K
    Radiat Environ Biophys; 2018 Mar; 57(1):55-61. PubMed ID: 29149420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and Safety of Retreatment with
    Delpassand ES; Yazdi SM; Ghantoji S; Nakasato A; Strickland C; Nunez R; Shafie A; Cork S; Byrne C; Tang J; Patel J
    J Nucl Med; 2024 May; 65(5):746-752. PubMed ID: 38514088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.
    Delpassand ES; Samarghandi A; Zamanian S; Wolin EM; Hamiditabar M; Espenan GD; Erion JL; O'Dorisio TM; Kvols LK; Simon J; Wolfangel R; Camp A; Krenning EP; Mojtahedi A
    Pancreas; 2014 May; 43(4):518-25. PubMed ID: 24632546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
    Ranade R; Basu S
    J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant
    Parghane RV; Bhandare M; Chaudhari V; Ostwal V; Ramaswamy A; Talole S; Shrikhande SV; Basu S
    J Nucl Med; 2021 Nov; 62(11):1558-1563. PubMed ID: 33637590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with
    Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L
    Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study.
    Partelli S; Landoni L; Bartolomei M; Zerbi A; Grana CM; Boggi U; Butturini G; Casadei R; Salvia R; Falconi M
    Br J Surg; 2024 Aug; 111(9):. PubMed ID: 39213395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the Radiobiological Mechanisms Induced by
    Delbart W; Karabet J; Marin G; Penninckx S; Derrien J; Ghanem GE; Flamen P; Wimana Z
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome.
    Zandee WT; Brabander T; Blažević A; Minczeles NS; Feelders RA; de Herder WW; Hofland J
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3665-e3672. PubMed ID: 33942075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT?
    Zemczak A; Kołodziej M; Gut P; Królicki L; Kos-Kudła B; Kamiński G; Ruchała M; Pawlak D; Kunikowska J
    Endokrynol Pol; 2020; 71(3):240-248. PubMed ID: 32293704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vivo Instability of
    Lubberink M; Wilking H; Öst A; Ilan E; Sandström M; Andersson C; Fröss-Baron K; Velikyan I; Sundin A
    J Nucl Med; 2020 Sep; 61(9):1337-1340. PubMed ID: 32005767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different technical possibilities of post-therapeutic tandem 90Y/ /177Lu-DOTATATE imaging.
    Kunikowska J; Bajera A; Sawicka M; Czwarnowski P; Pawłowicz B; Aksamit D; Pawlak D; Królicki L
    Nucl Med Rev Cent East Eur; 2013; 16(2):70-4. PubMed ID: 24068636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical score for neuroendocrine tumor patients under consideration for Lu-177-DOTATATE therapy.
    Das S; Du L; Schad A; Jain S; Jessop A; Shah C; Eisner D; Cardin D; Ciombor K; Goff L; Bradshaw M; Delbeke D; Sandler M; Berlin J
    Endocr Relat Cancer; 2021 Mar; 28(3):203-212. PubMed ID: 33608484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.